Clinical Trial to Evaluate the Safety and Appropriateness of Switching from Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People With HIV, Good Control and Neuropsychiatric Vulnerabilities: MIND Study

Other illness

• Allergy or intolerance to any of the components of BIC/FTC/TAF
• History of active CNS infections

Lab values

• Any clinical or laboratory condition that in the opinion of the investigator will prevent the participant to complete the study procedures

Age

• Pregnant or lactating women, as well as women of childbearing age who do not commit to use at least two contraceptive methods

Other

• Active psychosis or suicidal ideation
• Participant included in the neuroimaging substudy: Claustrophobia or presence of magnetizable body devices

• Adult >18 years diagnosed with HIV by standard microbiological techniques
• Active antiretroviral treatment with DTG/3TC
• Last HIV viral load performed on the participant in the 6 months prior to the visit screening < 50 copies/mL. If the participant does not have an HIV viral load <50 cop/mL performed in the 14 days prior to the screening visit, it will be necessary to confirm at screening visit that the participant's HIV viral load is <50 cop/mL
• Prior clinical diagnosis, carried out by a qualified specialist physician, of any of the following pathologies: Insomnia Anxiety disorders Depressive disorders